What the FDA labels say about taking them together
Belatacept and mycophenolate mofetil
Belatacept's FDA label of July 28, 2021 names mycophenolate mofetil in its drug interactions section; the mycophenolate mofetil labels PlainMeds reads (2) do not name belatacept. The belatacept label: “DRUG INTERACTIONS 7.1 Mycophenolate Mofetil (MMF) Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when a patient’s therapy is switched between cyclosporine and NULOJIX, as cyclosporine …”
Check it at the source: the belatacept FDA label on DailyMed (effective July 28, 2021, E.R. Squibb & Sons, L.L.C.); the mycophenolate mofetil FDA label on DailyMed (effective August 5, 2026, Genentech, Inc.).
What does the belatacept label say about mycophenolate mofetil?
Belatacept label, drug interactionsDRUG INTERACTIONS 7.1 Mycophenolate Mofetil (MMF) Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when a patient’s therapy is switched between cyclosporine and NULOJIX, as cyclosporine decreases mycophenolic acid (MPA) exposure by preventing enterohepatic recirculation of MPA while NULOJIX does not [see Clinical Pharmacology (12.3) ]:
Belatacept label, warnings and precautionsIn clinical trials with NULOJIX, two cases of PML were reported in patients receiving NULOJIX at higher cumulative doses and more frequently than the recommended regimen, along with mycophenolate mofetil (MMF) and corticosteroids; one case occurred in a kidney transplant recipient and the second case occurred in a liver transplant recipient [see Warnings and Precautions (5.6), Adverse Reactions (6.1), Clinical Studies (14.2) ].
Source: FDA drug label (NULOJIX), E.R. Squibb & Sons, L.L.C., effective July 28, 2021 (SPL set c16ac648-d5d2-9f7d-8637-e2328572754e), via openFDA; the full label on DailyMed
What does the mycophenolate mofetil label say about belatacept?
Mycophenolate mofetil's label (effective August 5, 2026) and its 1 other brand-application label do not name belatacept in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (CellCept), NDA050722 (Roche Palo), as published by Genentech, Inc., effective August 5, 2026 (SPL set 37241e87-4af4-4dc3-a1aa-ea6f20d8dc40), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Belatacept | Mycophenolate mofetil | |
|---|---|---|
| Labeled for | Organ transplant rejection | Organ transplant rejection |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.138 per capsule 250 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once